Elaine J. Heron, Ph.D. rejoined our Board in December 2024. She previously served on our Board from July 2018 to August 2022. From February 2009 to October 2015, Dr. Heron served as Chair and CEO of Amplyx Pharmaceuticals, Inc., a private drug development company acquired by Pfizer, Inc. in April 2021.
Dr. Heron currently serves on the boards of BioMarin Pharmaceutical Inc. (BMRN), a commercial stage company with eight marketed products including seven with orphan designation, Vaxart, Inc. (VXRT), a public clinical-stage biotechnology company which is developing oral vaccines, Visgenx, Inc., a private early-stage ophthalmology company, BlueWhale Bio, a private early-stage company developing products for cell therapy manufacturing, and Watershed Therapeutics, Inc., a private early-stage urology company. Dr. Heron is also an advisor to K2X Technology and Life Science, Inc., a FinTech company developing a vehicle for investing in early-stage companies.
From July 2001 to October 2008, Dr. Heron was Chair and CEO of Labcyte Inc., a private biotechnology tools company. Before joining Labcyte Inc., she spent six years in positions of increasing responsibility at the Applied Biosystems Group of Applera Corporation, a biotechnology tools company, including the positions of General Manager and Vice President of Sales and Marketing.
Dr. Heron holds a B.S. in Chemistry with highest distinction and a Ph.D. in Analytical Biochemistry from Purdue University and an M.B.A. from Pepperdine University.
What is Elaine J. Heron's net worth?
The estimated net worth of Elaine J. Heron is at least $6.54 million as of February 27th, 2026. Heron owns 47,812 shares of Palvella Therapeutics stock worth more than $6,535,900 as of March 10th. This net worth approximation does not reflect any other investments that Heron may own. Learn More about Elaine J. Heron's net worth.
How do I contact Elaine J. Heron?
Has Elaine J. Heron been buying or selling shares of Palvella Therapeutics?
During the last quarter, Elaine J. Heron has bought $300,000.00 in shares of Palvella Therapeutics stock. Most recently, on Friday, February 27th, Elaine J. Heron bought 2,400 shares of Palvella Therapeutics stock. The stock was acquired at an average cost of $125.00 per share, with a total value of $300,000.00. Following the completion of the transaction, the director now directly owns 47,812 shares of the company's stock, valued at $5,976,500. Learn More on Elaine J. Heron's trading history.
Who are Palvella Therapeutics' active insiders?
Are insiders buying or selling shares of Palvella Therapeutics?
In the last twelve months, Palvella Therapeutics insiders bought shares 3 times. They purchased a total of 8,900 shares worth more than $850,325.00. In the last twelve months, insiders at the sold shares 3 times. They sold a total of 12,906 shares worth more than $1,205,979.66. The most recent insider tranaction occured on February, 27th when Director George M Jenkins bought 4,000 shares worth more than $500,000.00. Insiders at Palvella Therapeutics own 20.5% of the company.
Learn More about insider trades at Palvella Therapeutics. Information on this page was last updated on 2/27/2026.
